Risk contribution of comorbidities in hospitalized patients with Covid 19 pneumonia

Background: The Covid 19 pandemic has a vast socioeconomic impact worldwide. Obtaining information about the course of the disease is vital for better management.Aim: To assess the risk, comorbidities (CMs) and mortality in hospitalized patients with Covid 19 pneumonia.Methods: The information was gathered from the medical registry and statistical analysis was performed using SPSS.Results: A total of 337 patient were analyzed. Males were 197 (58,5%). Positive PCR results had 307 (91,1%) patients. Almost half of the patients were with respiratory failure on admission (47,1%). At least one comorbidity was found in 84,6%. From the 38 patients that died (11,3%) all had CMs.Patients who died were older (74 vs 62, p<0,0001) and had more elevated leukocytes (16,5 vs 9,4, p<0,0001), CRP (157,9 vs 106,3, p<0,002), LDH (1003 vs 691, p<0,0001), AST (97 vs 45, p<0,0001), ALT (74 vs 46, p<0,0001), CPK (382 vs 151, p<0,0001), CPK-MB (55 vs 28, p<0,0001).Mortality risk assessed using Odds ratio was higher in patients with CMs: 2,3 (1,0-5,1 95% CI) for hypertension, 13,8 (5,5-34,1 95% CI) for IHD, 9,3 (4,4-19,5 95% CI) for arrythmias, 10,2 (4,7-22,1 95% CI) for CSVD. Respiratory failure on admission was related to poor prognosis and mortality (15,1% vs 1,6%, p<0,008).From all patients 12 (3,6%) had impaired glucose tolerance and required therapy after discharge. Other complications were: 3 patients with MI, 2 – with stroke, 1 – with arrythmia, 1 –...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections and bronchiectasis Source Type: research